NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
August 24, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
August 15, 2023 12:07 ET
|
NKGen Biotech, Inc.
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company’s Securities to be Listed on Nasdaq Under Ticker Symbols “NKGN”...
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company
August 09, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference
July 17, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Announces Poster Presentation at the 2023 Alzheimer’s Association International Conference
July 10, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
July 06, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of...
NKGen Biotech to Present at the 2nd International Alzheimer’s Disease & Dementia Conference 2023
June 13, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 13:05 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium
June 21, 2022 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...